Zika vaccine: Inovio expects to test vaccine in humans in 2016

Inovio Pharmaceuticals, Inc. announced today that preclinical testing of its synthetic vaccine for the Zika virus induced robust and durable immune responses, demonstrating the potential for a SynCon(R) vaccine to prevent and treat infections from this harmful pathogen. Health authorities have observed neurological and autoimmune complications potentially associated with Zika virus, including microcephaly in newborns ["]